A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide

@article{Nappi2013ARE,
  title={A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide},
  author={Jean Nappi},
  journal={Pharmacy Practice},
  year={2013},
  volume={11},
  pages={44 - 50}
}
  • J. Nappi
  • Published 2013
  • Medicine
  • Pharmacy Practice
Background The potency of intravenous bumetanide to furosemide using a ratio of 1:40 has been suggested; however, there are little data supporting this ratio. Recent drug shortages required the use of bumetanide in a large patient population, enabling further characterization of the efficacy of IV bumetanide. Objective The primary objective of this study was to estimate a dose-response effect of IV bumetanide on urine output (UOP) in all patients that received 48 hours of therapy as well as in… Expand

Figures, Tables, and Topics from this paper

Treatment outcomes of bumetanide continuous infusion: A systematic review and meta‐analysis
TLDR
With available evidence, continuous bumetanide infusion may be used in the treatment of acute heart failure or volume overload with close monitoring for new‐onset or worsening AKI. Expand
Subdiuretic dose of furosemide enhances albuterol effects in asthmatic mice rather than bumetanide.
TLDR
Inhaled subdiuretic dose of furosemide enhanced effects of albuterol more in ovalbumin-asthmatic mice rather than bumetanide, while oral diuretic doses of both drugs failed to improve asthma, indicating that this enhancing effect is not diUREtic-related. Expand
Aggressive Versus Conservative Initial Diuretic Dosing in the Emergency Department for Acute Decompensated Heart Failure
TLDR
Patients who received an aggressive initial diuretic dose in the ED had a significantly faster time to oral diuretics therapy without any significant differences in hospital LOS, urine output, change in body weight, and renal function when compared with conservative dosing. Expand
How to prescribe loop diuretics in oedema
TLDR
Evidence was gathered over a 15 year period in response to patient and physician queries regarding the management of oedema and the use of loop diuretics. Expand
Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures
TLDR
Key developmental differences in γ‐aminobutyric acid (GABA)ergic neurotransmission between the immature and mature brain, and trauma‐induced alterations in the function of the cation‐chloride cotransporters (CCCs) NKCC1 and KCC2, probably contribute to the poor efficacy of standard antiepileptic drugs used in the treatment of neonatal seizures. Expand
Quality of acute heart failure treatment in France: Data from REseau Nord-Alpin des Urgences (RENAU).
TLDR
The early management of patients with acute pulmonary oedema (as a marker of acute heart failure) in France in 2013 was quite different to recommendations published in 2015, and a programme to implement the new recommendations is in place. Expand
Cardiovascular Drug Shortages
TLDR
This article reviews 13 of the critical CV drug shortages, describe their role in therapy, discuss the reasons for the shortage, define their impact on patient care, and recommend alternative therapies. Expand
Inhibition of NKCC1 Modulates Alveolar Fluid Clearance and Inflammation in Ischemia-Reperfusion Lung Injury via TRAF6-Mediated Pathways
TLDR
Inhibition of NKCC1 by bumetanide reciprocally modulated epithelial p38 MAPK and NF-κB via TRAF6 in IR-ALI and attenuated the reduction of AFC via upregulating ENaC expression and reduced lung inflammation. Expand
Acute Hyperglycemia Aggravates Lung Injury via Activation of the SGK1–NKCC1 Pathway
TLDR
The NKCC1 inhibitor can effectively attenuate lung injury aggravated by acute hyperglycemia and reduce pulmonary edema, inflammation, levels of pro-inflammatory cytokines, neutrophils and AM1 and increased AM2. Expand
Inhibition of Na‐K‐Cl cotransporter isoform 1 reduces lung injury induced by ischemia–reperfusion
TLDR
Functional reduction of sodium‐potassium‐chloride co‐transporter by genetic or pharmacologic treatment to inhibit sodium‐ Potassium‐ chloride co-transporter resulted in lower severity of acute lung injury induced by ischemia–reperfusion, a promising target for therapeutic interventions in a clinical setting. Expand
...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
Clinical Trial of Bumetanide Versus Furosemide in Patients with Congestive Heart Failure
  • L. Konecke
  • Medicine
  • Journal of clinical pharmacology
  • 1981
TLDR
Both diuretics proved equally effective in reducing edema, and the effective dose ratio of bumetanide:furosemide was 1:25. Expand
Bumetanide and furosemide in heart failure.
TLDR
Both bumetanide and furosemide showed delayed absorption causing attainment of peak urinary excretion rates of diuretic two- to threefold lower than in normal subjects, which may contribute to the "resistance" to oral doses of diUREtics observed clinically even though no quantitative malabsorption of drug occurs. Expand
Comparative Efficacy and Safety of Bumetanide and Furosemide in Long‐Term Treatment of Edema Due to Congestive Heart Failure
TLDR
Both diuretics proved to be effective in the treatment of cardiac edema and other manifestations of heart failure and continued safety as well as efficacy in patients treated with bumetanide. Expand
Comparison of loop diuretics in patients with chronic renal insufficiency.
TLDR
Assessing the pharmacokinetic and pharmacodynamic characteristics of intravenously administered furosemide and bumetanide in ten adult patients with stable, chronic renal insufficiency in a randomized, cross-over study during controlled sodium intake found differences in diuretic effectiveness. Expand
Long‐Term Bumetanide Treatment of Renal Edema. Comparison with Furosemide
  • A. Whelton
  • Medicine
  • Journal of clinical pharmacology
  • 1981
TLDR
While a daily dose of 4.2 mg bumetanide is highly effective in severe renal edema, the design of the study did not warrant definitive conclusion regarding comparative efficacy with furosemide. Expand
Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.
Bumetanide is a potent 'loop' diuretic for the treatment of oedema associated with congestive heart failure, hepatic and renal diseases, acute pulmonary congestion and premenstrual syndrome and inExpand
Electrolyte Excretion Patterns. Intravenous and Oral Doses of Bumetanide Compared to Furosemide
TLDR
The time course of response shows that the curves are virtually superimposable and if bumetanide offers therapeutic advantages in this regard, studies in patients with various disease states would have to be performed. Expand
Continuous versus intermittent infusion of furosemide in acute decompensated heart failure.
TLDR
The cIV of furosemide was well tolerated and significantly more effective than iIV for tUOP, and continuous infusion appears to provide more efficient diuresis. Expand
Diuretic action of bumetanide in advanced chronic renal insufficiency
TLDR
Bumetanide 8 mg was less potent than furosemide 250 mg, a finding in contrast to the potency ratio of 1/40 in other conditions, and there was no relationship between the occurrence of side effects and plasma bumetAnide levels, electrolyte levels or the renal excretion of bumetanides and electrolytes. Expand
The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.
TLDR
A poor pharmacodynamic response and a reduced bumetanide excretion rate were observed for the patients with chronic renal failure, whereas with hepatic disease normal bumetanical excretion rates were observed with an impaired diuretic response. Expand
...
1
2
3
4
...